Intravitreal bevacizumab has initial clinical benefit lasting eight weeks in eyes with neovascular age-related macular degeneration. (Q37236127)
Jump to navigation
Jump to search
scientific article published on December 2008
Language | Label | Description | Also known as |
---|---|---|---|
English | Intravitreal bevacizumab has initial clinical benefit lasting eight weeks in eyes with neovascular age-related macular degeneration. |
scientific article published on December 2008 |
Statements
Intravitreal bevacizumab has initial clinical benefit lasting eight weeks in eyes with neovascular age-related macular degeneration (English)
P William Conrad
1 December 2008
1 reference
1 reference
1 reference